Danish infant scans link fetal paracetamol exposure to smaller ovaries

Forty per cent smaller by volume is the number that will travel, and it needs a translation. Ovarian volume on ultrasound is three linear measurements multiplied together, so a 40 per cent volume deficit corresponds to roughly a 16 per cent difference in linear size ^[21]. The 13 per cent uterine difference works out at about 4.5 per cent across a diameter ^[22]. That does not make the finding trivial, but it does put these measurements closer to the resolution of the instrument than the percentage suggests, and follicle counts ^[11] are the endpoint here least dependent on that arithmetic.

The design has a genuine virtue. The 685 women were asked about their medicines every two weeks during pregnancy rather than being asked to remember afterwards ^[10]. Recall of a tablet taken for a headache in week nine is poor by the time a baby arrives, and misclassified exposure normally blurs an association rather than manufacturing one. What the report does not give is how the 302 examined girls split between exposed and unexposed ^[23], and that split governs what a 40 per cent average difference is actually worth.

Dimitrios Siassakos at University College London raises the standard objection, which is the right one: the team ran many statistical analyses, and each one adds to the odds of a significant result arriving by chance ^[19]. The second dataset is the partial answer to that. A separate cohort of 1210 girls born in Copenhagen between 1997 and 2002 showed the same direction of effect on ovarian size, measured years later in adolescence ^[13]. Getting that twice, in different children at different ages, is harder to do by accident than getting it once.

Confounding by indication is the problem no amount of replication fixes. The women who took paracetamol had something wrong with them, mostly headaches or musculoskeletal pain ^[7], and the researchers note the association could reflect those underlying conditions rather than the drug ^[3]. The supporting evidence that makes anyone take this seriously comes from elsewhere: rodents, isolated human ovaries and human embryonic cells all point the same way ^[5]. Severine Mazaud-Guittot at France's National Institute of Health and Medical Research, who co-authored the 2022 isolated-ovary work, still says it is too early to remove paracetamol from the therapeutic arsenal, while arguing the precautionary principle applies in the first trimester ^[17][18].

The thing this study cannot tell you is whether any of these girls will have difficulty conceiving. Margit Bistrup Fischer says so directly, and the follow-up that would answer it is hard to run ^[15]. In animals, comparable effects did reduce fertility and bring reproductive ageing forward, which is why anyone is measuring infant ovaries at all ^[14], but the link from a three-month scan to an adult outcome is unestablished ^[4].

Which leaves a narrow practical line, and the researchers draw it themselves. High fever and strong pain still warrant paracetamol, because not treating them carries its own risk ^[6]. What is in question is the headache, and there the constraint is unusual: nearly every other painkiller is off the table in pregnancy because of congenital risk ^[9], so using less means rest, heat or physiotherapy rather than a different tablet ^[7]. Fischer's own framing is that it is still a drug with side effects, and maybe not the first thing to reach for at the first discomfort ^[8].